Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04719013 · ClinicalTrials.gov registry record · NA
Treatment With the Evoke System for Facial and Submental Laxity
A NA study, sponsored by InMode MD.
- Completed
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT04719013: Completed NA study, sponsored by InMode MD.
NCT04719013 is a NA study that has completed, run by InMode MD. The registered enrollment target is 85 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04719013, a NA study, has completed, sponsored by InMode MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the efficacy, patient comfort, and patient satisfaction after Evoke treatment for face and submental area
Primary Outcome
Evaluate change in skin appearance comparing pre and 6 months post last treatment photographs (as assessed by blinded investigators)
Interventions
- DEVICE Evoke radiofrequency device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-07-20 |
| Phase | NA |
What the finished NCT04719013 record still lists
NCT04719013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Evoke radiofrequency device is the first listed.
NCT04719013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04719013 about?
NCT04719013 is a clinical study titled "Treatment With the Evoke System for Facial and Submental Laxity". The aim of the study is to evaluate the efficacy, patient comfort, and patient satisfaction after Evoke treatment for face and submental area
What is the current status of trial NCT04719013?
This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2020-12-01. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT04719013?
The interventions under investigation include: Evoke radiofrequency device (DEVICE).
Who is sponsoring clinical trial NCT04719013?
This trial is sponsored by InMode MD, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04719013's enrollment target sits among peer trials
85 980th of 2000 higher than 1,018 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI